Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets

Michelle Ojemuyiwa, Karen Zeman, Alexander Spira, Bryan Oronsky, Carolyn Ray, Jane B. Trepel, Min Jung Lee, Ifeyinwa Onyiuke, Christina Brzezniak

Research output: Contribution to journalArticle

Abstract

Presented herein is the case of a heavily pretreated patient with high-grade neuroendocrine prostate cancer that achieved a complete metabolic response on platinum-based chemotherapy after treatment with the dual CD-47 and SIRP-α inhibitor, RRx-001, in a Phase II clinical trial.

Original languageEnglish (US)
JournalClinical Case Reports
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Neuroendocrine Carcinoma
Phase II Clinical Trials
Castration
Platinum
Prostate
Prostatic Neoplasms
Drug Therapy
Therapeutics
RRx-001

Keywords

  • macrophage repolarization
  • neuroendocrine cancer
  • platinum doublets
  • priming
  • prostate cancer
  • RRx-001

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets. / Ojemuyiwa, Michelle; Zeman, Karen; Spira, Alexander; Oronsky, Bryan; Ray, Carolyn; Trepel, Jane B.; Lee, Min Jung; Onyiuke, Ifeyinwa; Brzezniak, Christina.

In: Clinical Case Reports, 01.01.2018.

Research output: Contribution to journalArticle

Ojemuyiwa, Michelle ; Zeman, Karen ; Spira, Alexander ; Oronsky, Bryan ; Ray, Carolyn ; Trepel, Jane B. ; Lee, Min Jung ; Onyiuke, Ifeyinwa ; Brzezniak, Christina. / Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets. In: Clinical Case Reports. 2018.
@article{8bb6f3fd0ce143a9bc8be7c7d541daac,
title = "Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets",
abstract = "Presented herein is the case of a heavily pretreated patient with high-grade neuroendocrine prostate cancer that achieved a complete metabolic response on platinum-based chemotherapy after treatment with the dual CD-47 and SIRP-α inhibitor, RRx-001, in a Phase II clinical trial.",
keywords = "macrophage repolarization, neuroendocrine cancer, platinum doublets, priming, prostate cancer, RRx-001",
author = "Michelle Ojemuyiwa and Karen Zeman and Alexander Spira and Bryan Oronsky and Carolyn Ray and Trepel, {Jane B.} and Lee, {Min Jung} and Ifeyinwa Onyiuke and Christina Brzezniak",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/ccr3.1880",
language = "English (US)",
journal = "Clinical Case Reports",
issn = "2050-0904",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets

AU - Ojemuyiwa, Michelle

AU - Zeman, Karen

AU - Spira, Alexander

AU - Oronsky, Bryan

AU - Ray, Carolyn

AU - Trepel, Jane B.

AU - Lee, Min Jung

AU - Onyiuke, Ifeyinwa

AU - Brzezniak, Christina

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Presented herein is the case of a heavily pretreated patient with high-grade neuroendocrine prostate cancer that achieved a complete metabolic response on platinum-based chemotherapy after treatment with the dual CD-47 and SIRP-α inhibitor, RRx-001, in a Phase II clinical trial.

AB - Presented herein is the case of a heavily pretreated patient with high-grade neuroendocrine prostate cancer that achieved a complete metabolic response on platinum-based chemotherapy after treatment with the dual CD-47 and SIRP-α inhibitor, RRx-001, in a Phase II clinical trial.

KW - macrophage repolarization

KW - neuroendocrine cancer

KW - platinum doublets

KW - priming

KW - prostate cancer

KW - RRx-001

UR - http://www.scopus.com/inward/record.url?scp=85055999093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055999093&partnerID=8YFLogxK

U2 - 10.1002/ccr3.1880

DO - 10.1002/ccr3.1880

M3 - Article

C2 - 30564353

AN - SCOPUS:85055999093

JO - Clinical Case Reports

JF - Clinical Case Reports

SN - 2050-0904

ER -